Infection control wins stimulus funds

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

An investigator at Fred Hutchinson Cancer Center in Seattle has earned a $1.74 million grant under the American Recovery & Reinvestment Act of 2009.

An investigator at Fred Hutchinson Cancer Center in Seattle has earned a $1.74 million grant under the American Recovery & Reinvestment Act of 2009.

Recipient Colleen Delaney, MD, is an assistant member in the Fred Hutchinson center’s clinical research division. Her goal is to find to ways to reduce the risk of infection, and early death, in patients who receive cord blood transplants.

In her ongoing research, Dr. Delaney developed a novel culture methodology, which demonstrated that neutrophils can be generated from a single unit of cord blood. In addition, these cells are capable of rapid recovery when infused in the clinical setting. These findings could change the way transplant is done.

Recent Videos
Two experts are featured in this series.
Two experts are featured in this series.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
2 experts are featured in this series.
2 experts are featured in this series.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
2 experts are featured in this series.